Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 42

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 42
---
 and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with customary industry standards and practices.

(ii) .

| -21- |

(jj) . None of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the
Company participating in the offering contemplated hereby, any beneficial owner of 20% or more of the Company’s outstanding voting
equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities
Act) connected with the Company in any capacity at the time of sale (each, an “”) is subject to
any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company has exercised
reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event.

5. COVENANTS.

(a) . The Company agrees that it shall, within the time required under the Exchange Act, file
with the SEC a report on Form 6-K relating to the transactions contemplated by, and describing the material terms and conditions of, this
Agreement and the Registration Rights Agreement (the “”). The Company shall also file with the SEC, within
forty-five (45) calendar days from the Execution Date, a new registration statement on Form F-1 (the “”)
covering only the resale of up to [35,000,000] Purchase Shares and, if applicable, up to 875,000 Commitment Shares (in each case, assuming
the issuance and sale of such shares at the Floor Price per Depositary Share), in accordance with the terms of the Registration Rights
Agreement between the Company and the Investor, dated as of the Execution Date (the “”).
The Company shall permit the Investor to review and comment upon the substantially final pre-filing draft version of the Current Report
at least two (2) Business Days prior to its filing with the SEC, and the Company shall give due consideration to all such comments. The
Investor shall use its reasonable best efforts to comment upon the Current Report within one (1) Business Day from the date the Investor
receives the substantially